Sr. Director/Exec. Director of Cheminformatics for Early Molecule Discovery at Eli Lilly and Company

Indianapolis, Indiana, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, HealthcareIndustries

Requirements

Demonstrated ability of successfully applying in silico technologies to drive the discovery of quality lead-like molecules
Experience with cheminformatics, ML/AI, and advanced analytical approaches
Strong scientific leadership and strategic guidance on cheminformatics and applied ML/AI
Excellent people skills and a positive, can-do attitude
Ability to thrive in a highly interactive and fast-paced team environment
Hands-on experience applying cheminformatics and AI/ML technologies

Responsibilities

“Lead from the bench” by judiciously building up and applying state-of-the-art cheminformatics, ML/AI, and advanced analyses capabilities to enable library design, hit identification, prioritization, and hit-to-lead progression across multiple target classes and modalities
Provide scientific leadership and strategic guidance on cheminformatics and applied ML/AI approaches to drive data-driven drug discovery
Encourage close collaborations and initiatives with computational colleagues, medicinal chemists, and other cross-functional partners to generate well-poised molecules

Skills

Cheminformatics

Machine Learning

Artificial Intelligence

In Silico Technologies

Library Design

Hit Identification

Virtual Screening

Data-Driven Modeling

Advanced Analytics

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free